MedTrace Logo

Comparison of Intravenous V/S Nasal Atomizer Delivery of Midazolam for Conscious Sedation for No-scalpel Vasectomy

NCT06449365 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-06-10

No results posted yet for this study

Summary

Purpose: This study compared administration of midazolam via intravenous route with nasal atomizer route for moderate sedation in an office-based vasectomy clinic.

Conditions

  • Vasectomy
  • Sedation

Interventions

DEVICE

midazolam by nasal atomizer

midazolam

DRUG

intravenous midazolam

midazolam

Sponsors & Collaborators

  • University of Tennessee Graduate School of Medicine

    lead OTHER

Principal Investigators

  • Jennifer Ferris, Phd · UTGSM

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-22
Primary Completion
2020-08-07
Completion
2020-08-07
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06449365 on ClinicalTrials.gov